887 related articles for article (PubMed ID: 25510280)
1. Role of the ubiquitin proteasome system in hematologic malignancies.
Sahasrabuddhe AA; Elenitoba-Johnson KS
Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280
[TBL] [Abstract][Full Text] [Related]
2. Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy.
Goru SK; Kadakol A; Gaikwad AB
Pharmacol Res; 2017 Jun; 120():170-179. PubMed ID: 28363724
[TBL] [Abstract][Full Text] [Related]
3. Targeting the ubiquitin proteasome system in haematological malignancies.
Crawford LJ; Irvine AE
Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
[TBL] [Abstract][Full Text] [Related]
4. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy.
Allende-Vega N; Saville MK
Semin Cancer Biol; 2010 Feb; 20(1):29-39. PubMed ID: 19897040
[TBL] [Abstract][Full Text] [Related]
5. Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?
Lamsoul I; Uttenweiler-Joseph S; Moog-Lutz C; Lutz PG
Biochimie; 2016 Mar; 122():339-47. PubMed ID: 26253693
[TBL] [Abstract][Full Text] [Related]
6. The Multifaceted Role of the Ubiquitin Proteasome System in Pathogenesis and Diseases.
Stekel Z; Sheng Y; Zhang W
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883481
[TBL] [Abstract][Full Text] [Related]
7. Targeting the ubiquitin pathway for cancer treatment.
Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin-Proteasome Pathway and Muscle Atrophy.
Khalil R
Adv Exp Med Biol; 2018; 1088():235-248. PubMed ID: 30390254
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-Proteasome System in ABA Signaling: From Perception to Action.
Yu F; Wu Y; Xie Q
Mol Plant; 2016 Jan; 9(1):21-33. PubMed ID: 26455462
[TBL] [Abstract][Full Text] [Related]
10. E3 ubiquitin ligases in B-cell malignancies.
Choi J; Busino L
Cell Immunol; 2019 Jun; 340():103905. PubMed ID: 30827673
[TBL] [Abstract][Full Text] [Related]
11. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
Landré V; Rotblat B; Melino S; Bernassola F; Melino G
Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitination: Friend and foe in cancer.
Mansour MA
Int J Biochem Cell Biol; 2018 Aug; 101():80-93. PubMed ID: 29864543
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitination and the ubiquitin - proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma.
Voutsadakis IA
Anticancer Res; 2013 Sep; 33(9):3527-41. PubMed ID: 24023278
[TBL] [Abstract][Full Text] [Related]
14. Expanding the ubiquitin code in pancreatic cancer.
Yang W; Wang S; Tong S; Zhang WD; Qin JJ
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166884. PubMed ID: 37704111
[TBL] [Abstract][Full Text] [Related]
15. Proteasome substrate receptors and their therapeutic potential.
Osei-Amponsa V; Walters KJ
Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
[TBL] [Abstract][Full Text] [Related]
16. A patent review of the ubiquitin ligase system: 2015-2018.
Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitination and deubiquitination: Implications on cancer therapy.
Dagar G; Kumar R; Yadav KK; Singh M; Pandita TK
Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194979. PubMed ID: 37633647
[TBL] [Abstract][Full Text] [Related]
18. The role of aberrant proteolysis in lymphomagenesis.
Sahasrabuddhe AA; Elenitoba-Johnson KS
Curr Opin Hematol; 2015 Jul; 22(4):369-78. PubMed ID: 26049759
[TBL] [Abstract][Full Text] [Related]
19. Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.
Guharoy M; Bhowmick P; Tompa P
J Biol Chem; 2016 Mar; 291(13):6723-31. PubMed ID: 26851277
[TBL] [Abstract][Full Text] [Related]
20. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
